Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma

Table 2 Univariate and multivariate Cox proportional hazards regression of prognostic factors for overall survival

Characteristics	Univariate			Multivariate
Characteristics	HR	95% CI	P value	HR	95% CI	P value
Age (years; ≤ 50 vs. > 50)	0.878	0.647–1.192	0.403
Gender (male vs. female)	1.228	0.761–1.980	0.400
Smoke exposure (yes vs. no)	0.972	0.713–1.324	0.857
Alcohol exposure (yes vs. no)	1.055	0.759–1.465	0.751
Family history of cancer (yes vs. no)	0.924	0.641–1.333	0.673
Tumor size (< 5 cm vs. ≥ 5 cm)	4.332	2.896–6.482	< 0.001	1.973	1.230–3.164	0.005
TNM (I and II vs. III and IV)	0.211	0.152–0.293	< 0.001	0.470	0.319–0.693	< 0.001
Treatment exposure (Hepatic resection vs. others)	3.005	2.157–4.188	< 0.001	2.191	1.533–3.132	< 0.001
HBsAg (positive vs. negative)	0.820	0.536–1.256	0.362
AFP (ng / mL; < 400 vs. ≥ 400)	2.297	1.691–3.122	< 0.001	1.752	1.277–2.403	0.001
CRP (mg / L; < 6.70 vs. ≥ 6.70)	3.378	2.460–4.640	< 0.001	0.907	0.329–2.504	0.851
ALB (g / L; < 40 vs. ≥ 40)	0.665	0.490–0.902	0.009	0.960	0.691–1.333	0.807
ALT (U / L; < 40 vs. ≥ 40)	1.178	0.862–1.610	0.304
AST (U / L; < 45 vs. ≥ 45)	1.022	0.753–1.387	0.889
PLT (*10ˆ9 / L; < 100 vs. ≥ 100)	1.314	0.823–2.097	0.253
NLR (< 2.3 vs. ≥ 2.3)	0.963	0.709–1.307	0.808
PCR (< 47.8 vs. ≥ 47.8)	0.323	0.229–0.457	< 0.001	0.886	0.506–1.551	0.672
ACR (≤ 5.4 vs. > 5.4)	0.302	0.221–0.413	< 0.001	0.544	0.385–0.769	0.001

List of Abbreviations: HBsAg hepatitis B surface antigen, AFP alpha-fetoprotein, CRP C-reactive protein, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, PLT platelet, NLR neutrophil-to-lymphocyte ratio, PCR platelet -to-CRP ratio, ACR albumin-to-CRP ratio

ISSN: 1471-2407